Barclays analyst Luke Sergott raised the firm’s price target on Certara (CERT) to $13 from $12 and keeps an Equal Weight rating on the shares.

Q4 2024 Earnings Call Transcript February 26, 2025 Certara, Inc. beats earnings expectations. Reported EPS is $0.15, expectations were $0.13. Operator: Good day, and thank you for standing by. Welcome ...

RADNOR, Pa., Feb. 26, 2025 (GLOBE NEWSWIRE) -- Certara, Inc. (Nasdaq: CERT), a global leader in model-informed drug development, today reported its financial results for the fourth quarter and full ...

Certara (CERT) delivered earnings and revenue surprises of 15.38% and 0.68%, respectively, for the quarter ended December 2024. Do the numbers hold clues to what lies ahead for the stock?

Certara reported 14% revenue growth in Q4 2024, with significant increases in software and services revenue, and positive net income. Despite reporting positive revenue growth, the company still ...

Certara Inc (CERT) reports a robust 14% increase in fourth-quarter revenue, driven by software growth and strategic ...

Certara Inc . (NASDAQ: NASDAQ:CERT), a biosimulation software company with a market capitalization of approximately $2 billion, reported its fourth-quarter earnings for 2024 on February 26, showcasing ...

Welcome to the Certara fourth-quarter 2024 earnings conference call. (Operator Instructions) Please be advised that today's conference is being recorded. I would now like to hand the conference over ...

Good day, and thank you for standing by. Welcome to the Certara Fourth Quarter 2024 Earnings Conference Call. At this time, all participants are in a listen-only mode. After the speaker's ...